Compare CNS & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNS | SUPN |
|---|---|---|
| Founded | 1986 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.0B |
| IPO Year | 2004 | 2010 |
| Metric | CNS | SUPN |
|---|---|---|
| Price | $74.75 | $44.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $71.50 | $61.60 |
| AVG Volume (30 Days) | 200.1K | ★ 536.4K |
| Earning Date | 04-16-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $427,536,000.00 | $392,755,000.00 |
| Revenue This Year | $4.71 | $22.70 |
| Revenue Next Year | $4.37 | $19.14 |
| P/E Ratio | $91.01 | ★ N/A |
| Revenue Growth | ★ 4.07 | N/A |
| 52 Week Low | $58.39 | $31.16 |
| 52 Week High | $78.81 | $59.68 |
| Indicator | CNS | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 56.66 | 40.36 |
| Support Level | $59.88 | $43.67 |
| Resistance Level | $78.69 | $52.36 |
| Average True Range (ATR) | 2.05 | 1.43 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 64.29 | 46.73 |
Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for around two-thirds of its $98.4 billion in managed assets at the end of February. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (25%) of its managed assets (base management fees) from institutional clients, 48% (55%) from open-end funds, and 13% (20%) from closed-end funds.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.